- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06162572
Платформенное исследование фазы 1b/2 отдельных комбинаций иммунотерапии у участников с распространенным немелкоклеточным раком легких (НМРЛ)
Фаза 1b/2, многоцентровое открытое платформенное исследование избранных комбинаций иммунотерапии у взрослых участников с ранее не леченным распространенным немелкоклеточным раком легких (НМРЛ) с высокой экспрессией PD-L1
This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered for a maximum of 108 weeks, or until confirmed disease progression per iRECIST and/ or until meeting other treatment discontinuation criteria.
Обзор исследования
Статус
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Места учебы
-
-
-
Albury, Австралия, 2640
- Border Medical Oncology Research Unit
-
Bedford Park, Австралия, 5042
- Flinders Medical Centre
-
St Albans, Австралия, 3021
- Sunshine Hospital
-
Traralgon, Австралия, 3844
- Latrobe Regional Health
-
-
-
-
-
Sankt Pölten, Австрия, 3100
- Universitatsklinikum St. Poelten
-
Vienna, Австрия, 1090
- Medical University of Vienna - Akh
-
-
-
-
-
Hasselt, Бельгия, 3500
- Jessa Ziekenhuis
-
-
-
-
-
Barretos, Бразилия, 14784-400
- Hospital de Amor - Barretos
-
Chapecó, Бразилия, 89812618
- Supera Oncologia
-
Curitiba, Бразилия, 80810-050
- CIONC
-
Natal, Бразилия, 59035-055
- Liga Contra O Cancer - Natal
-
Porto Alegre, Бразилия, 90020-090
- Santa Casa de Porto Alegre
-
Porto Alegre, Бразилия, 90619-900
- Hospital São Lucas Da Pucrs
-
Rio de Janeiro, Бразилия, 22250-905
- Oncoclinicas Rj
-
São Paulo, Бразилия, 01509-010
- Hospital A C Camargo
-
São Paulo, Бразилия, 03102-002
- Hospital São Camilo
-
São Paulo, Бразилия, 04538-132
- Oncoclinicas Sp
-
São Paulo, Бразилия, 05652-900
- Hospital Albert Einstein
-
-
-
-
-
Farkasgyepű, Венгрия, 8582
- Farkasgyepu Tudogyogyintezet
-
Gyöngyös, Венгрия, 3200
- Bugat Pal Hospital
-
Pécs, Венгрия, 7624
- Pecsi Tudomanyegyetem, Klinikai Kozpont
-
-
-
-
-
Hong Kong, Гонконг
- Queen Mary Hospital
-
-
-
-
-
Barcelona, Испания, 08035
- Vall D' Hebron Institute of Oncology (Vhio), University Hospital
-
Madrid, Испания, 28007
- Hospital General Universitario Gregorio Marañón
-
Madrid, Испания, 28027
- Clinica Universitaria de Navarra (Madrid)
-
Madrid, Испания, 28050
- Hospital Univ. Hm Sanchinarro Start Ciocc Early Phase
-
Málaga, Испания, 29010
- Hospital Universitario Virgen de La Victoria
-
Valencia, Испания, 46026
- Hospital Universitario Y Politecnico La Fe
-
-
-
-
-
Aviano, Италия, 33081
- Centro Di Riferimento Oncologico
-
Meldola, Италия, 47014
- Inst. Romagnolo Per Lo Studio E La Cura Dei Tumori
-
Milan, Италия, 20162
- ASST Grande Ospedale Metropolitano Niguarda
-
Milan, Италия, 20133
- Irccs Fondazione Istituto Nazionale Dei Tumori
-
Milan, Италия, 20141
- Istituto Europeo Di Oncologia
-
Naples, Италия, 80131
- Ist. Nazionale Tumori Irccs Fondazione G Pascale
-
Perugia, Италия, 06132
- Azienda Ospedaliera S. Maria Della Misericordia
-
Roma, Италия, 00144
- Istituto Nazionale Tumori Regina Elena
-
Rozzano, Италия, 20089
- Istituto Clinico Humanitas I.R.C.C.S
-
-
-
-
-
Cluj-Napoca, Румыния
- Inst Oncologic "Prof Dr I Chiricuta" Cluj Napoca
-
-
-
-
-
London, Соединенное Королевство, SW3 6JJ
- The Royal Marsden in Chelsea
-
London, Соединенное Королевство, SM2 5PT
- The Royal Marsden in Sutton
-
Manchester, Соединенное Королевство, M20 4BX
- The Christie Nhs Foundation Foundation Trust
-
-
-
-
Michigan
-
Detroit, Michigan, Соединенные Штаты, 48202
- Henry Ford Health
-
-
Ohio
-
Canton, Ohio, Соединенные Штаты, 44718
- Gabrail Cancer Center
-
Columbus, Ohio, Соединенные Штаты, 43210
- Ohio State University Comprehensive Cancer Center
-
-
-
-
-
Taipei, Тайвань, 100225
- National Taiwan University Hospital
-
Taipei, Тайвань, 114202
- Tri-Service General Hospital
-
-
-
-
-
Dijon, Франция, 21079
- Centre Georges Francois Leclerc
-
Grenoble, Франция, 38043
- Chu Grenoble Alpes
-
Marseille, Франция, 13009
- Institut Paoli Calmette
-
Saint-Herblain, Франция, 44805
- Centre René Gauducheau/Inst de Cancér. de L'Ouest
-
Villejuif, Франция, 94805
- Institut Gustave Roussy
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Adult patient aged ≥ 18 years
- Written informed consent
- Histologically (squamous or non-squamous) or cytologically documented locally advanced NSCLC not eligible for surgical resection and/or definitive chemoradiation, or metastatic NSCLC
- No prior systemic treatment for locally advanced or metastatic NSCLC
- High tumor cell PD-L1 expression [Tumor Proportion Score (TPS) ≥50%] based on documented status as determined by an approved test
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Measurable disease as determined by RECIST v1.1
Exclusion Criteria:
- Tumors harboring driver mutations/genetic aberrations for which targeted therapies are approved as frontline treatment (e.g. EGFR mutation, ALK fusion oncogene, ROS1 aberrations)
- Prior immune checkpoint inhibitor therapy
- Active brain metastases
- Participants with active and uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- Uncontrolled HIV infection. Participants with HIV who have controlled infection (undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen) are allowed to enroll
- Active, known or suspected autoimmune disease or immune deficiency
- History of hypersensitivity reactions to any ingredient of the investigational medicinal product (IMP) and other monoclonal antibody (mAbs) and/or their excipients
- History of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced pneumonitis, idiopathic pneumonitis or active pneumonitis ≥ grade 2
- History of inflammatory bowel disease or colitis ≥ grade 2
- History of hemophagocytic lymphohistiocytosis.
- Systemic chronic steroid therapy (>10mg/d prednisone or equivalent)
- Clinically significant infection, as assessed by the investigator
- Pregnant or breast-feeding (lactating) women
- Participants with a history of allogeneic organ transplantation (e.g., stem cell or solid organ transplant)
- Any medical condition that would in the investigator's judgement prevent the participant's participation in the clinical study
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: S095018 (anti-TIM3 antibody) in combination with cemiplimab
Part A: Combination-therapy safety lead-in |
Via IV infusion on Day 1 of each 21-day cycle 350 mg via IV infusion on Day 1 of each 21-day cycle |
|
Экспериментальный: S095024 (anti-CD73 antibody) in combination with cemiplimab
Part A: Combination-therapy safety lead-in |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Экспериментальный: S095029 (anti-NKG2A antibody) in combination with cemiplimab
Part A: Combination-therapy safety lead-in |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Экспериментальный: S095018 (anti-TIM3 antibody) RDE in combination with cemiplimab
Part B: Randomized dose expansion |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Экспериментальный: S095024 (anti-CD73 antibody) RDE in combination with cemiplimab
Part B: Randomized dose expansion |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Экспериментальный: S095029 (anti-NKG2A antibody) RDE in combination with cemiplimab
Part B: Randomized dose expansion |
350 mg via IV infusion on Day 1 of each 21-day cycle Via IV infusion on Day 1 of each 21-day cycle |
|
Активный компаратор: Cemiplimab (control arm)
Part B: Randomized dose expansion |
350 mg via IV infusion on Day 1 of each 21-day cycle |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Incidence and severity of dose-limiting toxicities (DLTs) during the first 2 cycles of combination treatment
Временное ограничение: Through the end of the Cycle 2 (each cycle is 21 days)
|
Part A |
Through the end of the Cycle 2 (each cycle is 21 days)
|
|
Incidence and severity of adverse events (AEs)
Временное ограничение: From the signed informed consent form (ICF) to 30 days after the last dose
|
Part A |
From the signed informed consent form (ICF) to 30 days after the last dose
|
|
Incidence and severity of serious adverse events (SAEs)
Временное ограничение: From the signed ICF to 120 days after the last dose
|
Part A |
From the signed ICF to 120 days after the last dose
|
|
Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays
Временное ограничение: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Part A |
From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
|
Adverse Events (AEs) Leading to Permanent Treatment Discontinuation
Временное ограничение: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Part A |
From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
|
Objective Response (OR)
Временное ограничение: Until study termination (approximately 2 years)
|
Part B: Participants who achieve complete response (CR) or partial response (PR), as per investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Until study termination (approximately 2 years)
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Objective Response (OR)
Временное ограничение: Until study termination (approximately 3 years)
|
Part A: Participants who achieve CR or PR, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator. |
Until study termination (approximately 3 years)
|
|
Best Overall Response (BOR)
Временное ограничение: Until study termination (approximately 3 years)
|
Part A and B: The best response designation using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST), recorded between the date of the first dose of treatment and the date of the first objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. CR or PR used in the BOR requires a confirmation that is at least 4 weeks apart. |
Until study termination (approximately 3 years)
|
|
Duration of Response (DoR)
Временное ограничение: Until study termination (approximately 3 years)
|
Part A and B: The time from the first documentation of CR or PR until the documented progressive disease (PD) or death, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator. |
Until study termination (approximately 3 years)
|
|
Disease Control (DC)
Временное ограничение: Until study termination (approximately 3 years)
|
Part A and B: Participants who achieved stable disease (SD), PR, or CR (based on participant's best response), as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator. |
Until study termination (approximately 3 years)
|
|
6-month Durable Response (6-month DR)
Временное ограничение: Until study termination (approximately 3 years)
|
Part A and B: Continuous CR or PR for ≥ 6 months, recorded between the date of the first dose of treatment and the date of the first objectively documented progression per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or the date of subsequent anti-cancer therapy, whichever occurs first. |
Until study termination (approximately 3 years)
|
|
Progression-Free Survival (PFS)
Временное ограничение: Until study termination (approximately 3 years)
|
Part A and B: The time from the first dose to the first documented PD or death due to any cause, whichever occurs first, as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune RECIST (iRECIST) as assessed by the investigator. |
Until study termination (approximately 3 years)
|
|
Plasma or serum concentration of S095018
Временное ограничение: From first dose to 30 days after the last dose
|
Part A and B |
From first dose to 30 days after the last dose
|
|
Plasma or serum concentration of S095024
Временное ограничение: From first dose to 30 days after the last dose
|
Part A and B |
From first dose to 30 days after the last dose
|
|
Plasma or serum concentration of S095029
Временное ограничение: From first dose to 30 days after the last dose
|
Part A and B |
From first dose to 30 days after the last dose
|
|
Incidence and titer of anti-drug antibodies (ADA) directed against S095018
Временное ограничение: From screening to 90 days after the last dose
|
Part A and B |
From screening to 90 days after the last dose
|
|
Incidence and titer of anti-drug antibodies (ADA) directed against S095024
Временное ограничение: From screening to 90 days after the last dose
|
Part A and B |
From screening to 90 days after the last dose
|
|
Incidence and titer of anti-drug antibodies (ADA) directed against S095029
Временное ограничение: From screening to 90 days after the last dose
|
Part A and B |
From screening to 90 days after the last dose
|
|
Incidence and severity of adverse events (AEs)
Временное ограничение: From signed ICF to 30 days after the last dose
|
Part B |
From signed ICF to 30 days after the last dose
|
|
Incidence and severity of serious adverse events (SAEs)
Временное ограничение: From signed ICF to 120 days after the last dose
|
Part B |
From signed ICF to 120 days after the last dose
|
|
Adverse Events (AEs) Leading to Dose Interruption, Modification, or Delays
Временное ограничение: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Part B |
From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
|
Adverse Events (AEs) Leading to Permanent Treatment Discontinuation
Временное ограничение: From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Part B |
From signed ICF through treatment discontinuation (up to 108 weeks of treatment)
|
Соавторы и исследователи
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- SPLFIO-174
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
Access can be requested for all interventional clinical studies:
- used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
- where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.
In addition, access can be requested for all interventional clinical studies in patients:
- sponsored by Servier
- with a first patient enrolled as of 1 January 2004 onwards
- for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
Сроки обмена IPD
After Marketing Authorization in EEA or US if the study is used for the approval.
Критерии совместного доступа к IPD
Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
- МКФ
- КСО
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .